(ALEC) Alector - Ratings and Ratios
Therapeutic, Antibodies, Neurodegeneration, Clinical Trials
ALEC EPS (Earnings per Share)
ALEC Revenue
Description: ALEC Alector
Alector Inc (NASDAQ:ALEC) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock performance and financials indicate a complex situation that warrants a detailed analysis.
The stocks recent price movement shows a level of volatility, with the last price recorded at $2.25. The stock has shown an upward trend relative to its short-term and long-term moving averages (SMA20, SMA50, and SMA200), suggesting a potential positive momentum. However, the stock is still below its 52-week high of $6.14, indicating a significant decline from its peak.
From a fundamental analysis perspective, Alectors market capitalization stands at $202.42 million, categorizing it as a small-cap company. The absence of a price-to-earnings (P/E) ratio is due to the companys negative earnings, a common trait among many biotech firms that are often in the development stage and not yet profitable. The forward P/E ratio is high at 526.32, suggesting that investors are pricing in significant future earnings growth. The Return on Equity (RoE) is negative at -112.06%, indicating that the company is currently not generating profits from shareholder equity.
Key Performance Indicators (KPIs) to watch for Alector include the progression of its pipeline assets, particularly those in clinical development. The companys ability to advance its products through clinical trials and eventually achieve commercialization will be crucial. Other important drivers include the cash runway, burn rate, and any potential partnerships or collaborations that could impact its financials and operational capabilities. The biotech sector is heavily influenced by regulatory approvals, so updates on FDA interactions and trial results will be significant.
Economic drivers influencing Alectors stock include the overall appetite for risk in the equity markets, sentiment towards the biotech sector, and broader healthcare trends. Interest rates and the availability of capital for biotech companies can also impact stock performance. Given the companys negative earnings and high forward P/E, investor sentiment is likely to be highly sensitive to news flow related to its clinical programs and financial management.
ALEC Stock Overview
| Market Cap in USD | 282m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-02-07 |
ALEC Stock Ratings
| Growth Rating | -77.3% |
| Fundamental | 43.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -56.2% |
| Analyst Rating | 3.89 of 5 |
ALEC Dividends
Currently no dividends paidALEC Growth Ratios
| Growth Correlation 3m | 86.3% |
| Growth Correlation 12m | -51.9% |
| Growth Correlation 5y | -93% |
| CAGR 5y | -32.14% |
| CAGR/Max DD 3y | -0.35 |
| CAGR/Mean DD 3y | -0.76 |
| Sharpe Ratio 12m | 0.93 |
| Alpha | -64.09 |
| Beta | 0.657 |
| Volatility | 80.31% |
| Current Volume | 925k |
| Average Volume 20d | 1039.1k |
| Stop Loss | 2.7 (-8.8%) |
| Signal | 1.40 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-115.3m TTM) > 0 and > 6% of Revenue (6% = 4.87m TTM) |
| FCFTA -0.65 (>2.0%) and ΔFCFTA -32.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 289.4% (prev 673.0%; Δ -383.6pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.60 (>3.0%) and CFO -215.6m <= Net Income -115.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (100.4m) change vs 12m ago 3.82% (target <= -2.0% for YES) |
| Gross Margin 36.06% (prev 91.40%; Δ -55.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 17.50% (prev 9.68%; Δ 7.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -9.22
| (A) 0.66 = (Total Current Assets 319.2m - Total Current Liabilities 84.4m) / Total Assets 356.4m |
| (B) -2.53 = Retained Earnings (Balance) -900.1m / Total Assets 356.4m |
| warn (B) unusual magnitude: -2.53 — check mapping/units |
| (C) -0.30 = EBIT TTM -137.7m / Avg Total Assets 463.6m |
| (D) -3.16 = Book Value of Equity -900.0m / Total Liabilities 285.2m |
| Total Rating: -9.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.95
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.26 = 2.47 |
| 5. Debt/Ebitda -0.14 = -2.50 |
| 7. RoE -112.1% = -2.50 |
| 8. Rev. Trend -27.06% = -2.03 |
| 9. EPS Trend 40.17% = 2.01 |
What is the price of ALEC shares?
Over the past week, the price has changed by +7.25%, over one month by +31.56%, over three months by +96.03% and over the past year by -47.89%.
Is Alector a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALEC is around 2.23 USD . This means that ALEC is currently overvalued and has a potential downside of -24.66%.
Is ALEC a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 1
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the ALEC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.8 | 29.4% |
| Analysts Target Price | 3.8 | 29.4% |
| ValueRay Target Price | 2.5 | -15.5% |
Last update: 2025-09-05 04:31
ALEC Fundamental Data Overview
CCE Cash And Equivalents = 307.3m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 526.3158
P/S = 3.4806
P/B = 3.683
Beta = 0.864
Revenue TTM = 81.1m USD
EBIT TTM = -137.7m USD
EBITDA TTM = -128.4m USD
Long Term Debt = 9.54m USD (from longTermDebt, last quarter)
Short Term Debt = 8.90m USD (from shortTermDebt, last quarter)
Debt = 18.4m USD (Calculated: Short Term 8.90m + Long Term 9.54m)
Net Debt = -5.29m USD (from netDebt column, last quarter)
Enterprise Value = -6.46m USD (282.4m + Debt 18.4m - CCE 307.3m)
Interest Coverage Ratio = unknown (Ebit TTM -137.7m / Interest Expense TTM 0.0)
FCF Yield = -3579 % (FCF TTM -231.2m / Enterprise Value -6.46m)
FCF Margin = -284.9% (FCF TTM -231.2m / Revenue TTM 81.1m)
Net Margin = -142.1% (Net Income TTM -115.3m / Revenue TTM 81.1m)
Gross Margin = 36.06% ((Revenue TTM 81.1m - Cost of Revenue TTM 51.9m) / Revenue TTM)
Tobins Q-Ratio = 0.01 (Enterprise Value -6.46m / Book Value Of Equity -900.0m)
Interest Expense / Debt = 27.98% (Interest Expense 5.16m / Debt 18.4m)
Taxrate = 21.0% (US default)
NOPAT = -137.7m (EBIT -137.7m, no tax applied on loss)
Current Ratio = 3.78 (Total Current Assets 319.2m / Total Current Liabilities 84.4m)
Debt / Equity = 0.26 (Debt 18.4m / last Quarter total Stockholder Equity 71.2m)
Debt / EBITDA = -0.14 (Net Debt -5.29m / EBITDA -128.4m)
Debt / FCF = -0.08 (Debt 18.4m / FCF TTM -231.2m)
Total Stockholder Equity = 102.9m (last 4 quarters mean)
RoA = -32.35% (Net Income -115.3m, Total Assets 356.4m )
RoE = -112.1% (Net Income TTM -115.3m / Total Stockholder Equity 102.9m)
RoCE = -122.5% (set to none) (Ebit -137.7m / (Equity 102.9m + L.T.Debt 9.54m))
RoIC = -125.2% (set to none) (NOPAT -137.7m / Invested Capital 110.0m)
WACC = 9.28% (E(282.4m)/V(300.8m) * Re(8.44%)) + (D(18.4m)/V(300.8m) * Rd(27.98%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.19 | Cagr: 1.79%
Discount Rate = 8.44% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -231.2m)
EPS Correlation: 40.17 | EPS CAGR: 75.74% | SUE: 0.63 | # QB: False
Revenue Correlation: -27.06 | Revenue CAGR: -20.61%
Additional Sources for ALEC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle